23 Works

Supplemental Material - Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
Supplemental Material for Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses by Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily and Olivier Espitia in Lupus

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter & Minyoung Jang
Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer’s perspective. Methods A prevalence-based budget impact model was developed to...

Additional file 1 of Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis

Francois Gouin, Eberhard Stoeckle, Charles Honoré, Mickael Ropars, Mehrdad Jafari, Jean Camille Mattei, Alexandre Rochwerger, Sébastien Carrere, Denis Waast, Gwenaël Ferron, Jean-Christophe Machiavello, Philippe Anract, Frédéric Marchal, François Sirveaux, Oren Marco, Jérôme Guiramand, Brice Paquette, Antonio Di Marco, Sylvain Causeret, Jean-Marc Guilloit, Pauline Soibinet, Dimitri Tzanis, Pierre Gimbergues, Fabrice Fiorenza, Franck Dujardin … & Jean-Yves Blay
Additional file 1: Supplementary material S1, S2, S3 and S4

Additional file 1 of Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Apolline Imbard, Artemis Toumazi, Sophie Magréault, Nuria Garcia-Segarra, Dimitri Schlemmer, Florentia Kaguelidou, Isabelle Perronneau, Jérémie Haignere, Hélène Ogier de Baulny, Alice Kuster, François Feillet, Corinne Alberti, Sophie Guilmin-Crépon, Jean-François Benoist & Manuel Schiff
Additional file 1: Table S1: Patients’ characteristics. Table S2: Detail of patient current treatment. Table S3: Clinical data at inclusion. Figure S1: Carry-over effect. Figure S2: plasma total homocysteine (tHcy) before and after one month treatment with 100 mg/kg/day) (A, D) or 250 mg/kg/day (B, E) in pnrCBS patients (A, B) and cblC patients (B, E) and the corresponding difference (ΔtHcy) for each pnrCBS (C) and cblC (F) patient. Figure S3: SAM (A, B), SAH...

Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis

Francois Gouin, Eberhard Stoeckle, Charles Honoré, Mickael Ropars, Mehrdad Jafari, Jean Camille Mattei, Alexandre Rochwerger, Sébastien Carrere, Denis Waast, Gwenaël Ferron, Jean-Christophe Machiavello, Philippe Anract, Frédéric Marchal, François Sirveaux, Oren Marco, Jérôme Guiramand, Brice Paquette, Antonio Di Marco, Sylvain Causeret, Jean-Marc Guilloit, Pauline Soibinet, Dimitri Tzanis, Pierre Gimbergues, Fabrice Fiorenza, Franck Dujardin … & Jean-Yves Blay
Abstract Background This French nationwide NETSARC exhaustive prospective cohort aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS) with positive microscopic margins (R1) after initial resection performed outside of a reference center. Methods Eligible patients had experienced STS surgery outside a reference center from 2010 to 2017, and had R1...

Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis

Francois Gouin, Eberhard Stoeckle, Charles Honoré, Mickael Ropars, Mehrdad Jafari, Jean Camille Mattei, Alexandre Rochwerger, Sébastien Carrere, Denis Waast, Gwenaël Ferron, Jean-Christophe Machiavello, Philippe Anract, Frédéric Marchal, François Sirveaux, Oren Marco, Jérôme Guiramand, Brice Paquette, Antonio Di Marco, Sylvain Causeret, Jean-Marc Guilloit, Pauline Soibinet, Dimitri Tzanis, Pierre Gimbergues, Fabrice Fiorenza, Franck Dujardin … & Jean-Yves Blay
Abstract Background This French nationwide NETSARC exhaustive prospective cohort aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS) with positive microscopic margins (R1) after initial resection performed outside of a reference center. Methods Eligible patients had experienced STS surgery outside a reference center from 2010 to 2017, and had R1...

Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
ObjectiveThe aim of the study was to describe clinical and biological characteristics and thrombotic relapses of patients diagnosed with antiphospholipid syndrome (APS) after the age of 65 years, in comparison with patients diagnosed with APS before 65.MethodsThis retrospective multicenter study was performed to 2005 from 2017 and included patients diagnosed with APS after the age of 65 years, in accordance with Sydney criteria. We compared these patients with APS patients diagnosed before the age of...

Additional file 1 of Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter & Minyoung Jang
Additional file 1.

Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Apolline Imbard, Artemis Toumazi, Sophie Magréault, Nuria Garcia-Segarra, Dimitri Schlemmer, Florentia Kaguelidou, Isabelle Perronneau, Jérémie Haignere, Hélène Ogier de Baulny, Alice Kuster, François Feillet, Corinne Alberti, Sophie Guilmin-Crépon, Jean-François Benoist & Manuel Schiff
Abstract Background Betaine is an “alternate” methyl donor for homocysteine remethylation catalyzed by betaine homocysteine methyltransferase (BHMT), an enzyme mainly expressed in the liver and kidney. Betaine has been used for more than 30 years in pyridoxine non-responsive cystathionine beta-synthase (pnrCBS) and cobalamin C (cblC) deficiencies to lower the hyperhomocysteinemia, although little is known about the optimal therapeutic dosage and its pharmacokinetic in these patients. Aims We compared 2 betaine doses (100 mg/kg/day vs. 250...

Data from: Genetic structure of the poplar rust fungus Melampsora larici-populina: Evidence for isolation by distance in Europe and recent founder effects overseas

Benoît Barrès, Fabien Halkett, Cyril Dutech, Axelle Andrieux, Jean Pinon & Pascal Frey
Dispersal has a great impact on the genetic structure of populations, but remains difficult to estimate by direct measures. In particular, gradual and stochastic dispersal are often difficult to assess and to distinguish, although they have different evolutionary consequences. Plant pathogens, especially rust fungi, are suspected to display both dispersal modes, though on different spatial scales. In this study, we inferred dispersal capacities of the poplar rust fungus Melampsora larici-populina by examining the genetic diversity...

Data from: Diffusion tensor imaging reveals diffuse white matter injuries in locked-in syndrome patients

Mylène L. Leonard, Felix R. Renard, Laura H. Harsan, Julien P. Pottecher, Marc B. Braun, Francis S. Schneider, Pierre F. Froehlig, Frédéric B. Blanc, Daniel R. Roquet, Sophie A. Achard, Nicolas M. Meyer & Stéphane K. Kremer
Locked-in syndrome (LIS) is a state of quadriplegia and anarthria with preserved consciousness, which is generally triggered by a disruption of specific white matter fiber tracts, following a lesion in the ventral part of the pons. However, the impact of focal lesions on the whole brain white matter microstructure and structural connectivity pathways remains unknown. We used diffusion tensor magnetic resonance imaging (DT-MRI) and tract-based statistics to characterise the whole white matter tracts in seven...

Supplemental Material - Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
Supplemental Material for Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses by Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily and Olivier Espitia in Lupus

Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
ObjectiveThe aim of the study was to describe clinical and biological characteristics and thrombotic relapses of patients diagnosed with antiphospholipid syndrome (APS) after the age of 65 years, in comparison with patients diagnosed with APS before 65.MethodsThis retrospective multicenter study was performed to 2005 from 2017 and included patients diagnosed with APS after the age of 65 years, in accordance with Sydney criteria. We compared these patients with APS patients diagnosed before the age of...

Additional file 1 of Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter & Minyoung Jang
Additional file 1.

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

Antoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, Jérôme Filippi, Romain Altwegg, Yoram Bouhnik, Melanie Serrero, David Laharie, Xavier Roblin, Maria Nachury, Vered Abitbol, Guillaume Cadiot, Stephane Nancey, Matthieu Allez, Cyrielle Gilletta, Lucine Vuitton, Guillaume Savoye, Stephane Nahon, Anne Bourrier, Anthony Buisson, Guillaume Bouguen, Arnaud Bourreille, Stephanie Viennot, Franck Carbonnel & Aurelien Amiot
There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted...

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

Antoine Meyer, Mathurin Fumery, Laurent Peyrin-Biroulet, Jérôme Filippi, Romain Altwegg, Yoram Bouhnik, Melanie Serrero, David Laharie, Xavier Roblin, Maria Nachury, Vered Abitbol, Guillaume Cadiot, Stephane Nancey, Matthieu Allez, Cyrielle Gilletta, Lucine Vuitton, Guillaume Savoye, Stephane Nahon, Anne Bourrier, Anthony Buisson, Guillaume Bouguen, Arnaud Bourreille, Stephanie Viennot, Franck Carbonnel & Aurelien Amiot
There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails. We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events. Propensity scores weighted...

Supplemental Material - Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
Supplemental Material for Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses by Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily and Olivier Espitia in Lupus

Additional file 1 of Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis

Francois Gouin, Eberhard Stoeckle, Charles Honoré, Mickael Ropars, Mehrdad Jafari, Jean Camille Mattei, Alexandre Rochwerger, Sébastien Carrere, Denis Waast, Gwenaël Ferron, Jean-Christophe Machiavello, Philippe Anract, Frédéric Marchal, François Sirveaux, Oren Marco, Jérôme Guiramand, Brice Paquette, Antonio Di Marco, Sylvain Causeret, Jean-Marc Guilloit, Pauline Soibinet, Dimitri Tzanis, Pierre Gimbergues, Fabrice Fiorenza, Franck Dujardin … & Jean-Yves Blay
Additional file 1: Supplementary material S1, S2, S3 and S4

Antiphospholipid syndrome in patients over 65 years: A comparative study of clinical and biological features and thrombotic relapses

Colombe Masson, Thi T. An Nguyen, Virginie Dufrost, Marie Audrain, Caroline Hémont, Christian Agard, Mathieu Artifoni, Jérôme Connault, Marc Fouassier, Mohamed Hamidou, Alexis F Guedon, Denis Wahl, Stéphane Zuily & Olivier Espitia
ObjectiveThe aim of the study was to describe clinical and biological characteristics and thrombotic relapses of patients diagnosed with antiphospholipid syndrome (APS) after the age of 65 years, in comparison with patients diagnosed with APS before 65.MethodsThis retrospective multicenter study was performed to 2005 from 2017 and included patients diagnosed with APS after the age of 65 years, in accordance with Sydney criteria. We compared these patients with APS patients diagnosed before the age of...

Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Apolline Imbard, Artemis Toumazi, Sophie Magréault, Nuria Garcia-Segarra, Dimitri Schlemmer, Florentia Kaguelidou, Isabelle Perronneau, Jérémie Haignere, Hélène Ogier de Baulny, Alice Kuster, François Feillet, Corinne Alberti, Sophie Guilmin-Crépon, Jean-François Benoist & Manuel Schiff
Abstract Background Betaine is an “alternate” methyl donor for homocysteine remethylation catalyzed by betaine homocysteine methyltransferase (BHMT), an enzyme mainly expressed in the liver and kidney. Betaine has been used for more than 30 years in pyridoxine non-responsive cystathionine beta-synthase (pnrCBS) and cobalamin C (cblC) deficiencies to lower the hyperhomocysteinemia, although little is known about the optimal therapeutic dosage and its pharmacokinetic in these patients. Aims We compared 2 betaine doses (100 mg/kg/day vs. 250...

Additional file 1 of Efficacy and pharmacokinetics of betaine in CBS and cblC deficiencies: a cross-over randomized controlled trial

Apolline Imbard, Artemis Toumazi, Sophie Magréault, Nuria Garcia-Segarra, Dimitri Schlemmer, Florentia Kaguelidou, Isabelle Perronneau, Jérémie Haignere, Hélène Ogier de Baulny, Alice Kuster, François Feillet, Corinne Alberti, Sophie Guilmin-Crépon, Jean-François Benoist & Manuel Schiff
Additional file 1: Table S1: Patients’ characteristics. Table S2: Detail of patient current treatment. Table S3: Clinical data at inclusion. Figure S1: Carry-over effect. Figure S2: plasma total homocysteine (tHcy) before and after one month treatment with 100 mg/kg/day) (A, D) or 250 mg/kg/day (B, E) in pnrCBS patients (A, B) and cblC patients (B, E) and the corresponding difference (ΔtHcy) for each pnrCBS (C) and cblC (F) patient. Figure S3: SAM (A, B), SAH...

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Hyun Kyeong Yoo, Han Geul Byun, Flavio Caprioli, Mathurin Fumery, Laurent Peyrin-Biroulet, Subramanian Sreedhar, James Potter & Minyoung Jang
Abstract Background In 2020, the European Medicines Agency approved infliximab subcutaneous (SC) for the treatment of inflammatory bowel disease. This new mode of infliximab administration will reduce outpatient visits and costs of intravenous (IV) administration. This article describes a budget impact analysis of introducing infliximab SC to the Big-5 European (E5) market (Germany, France, Italy, Spain and UK) for 5 years, from the healthcare payer’s perspective. Methods A prevalence-based budget impact model was developed to...

Registration Year

  • 2022
    21
  • 2019
    1
  • 2012
    1

Resource Types

  • Text
    11
  • Collection
    9
  • Dataset
    2
  • Journal Article
    1

Affiliations

  • Centre Hospitalier Universitaire de Nancy
    23
  • Centre Hospitalier Universitaire de Nantes
    9
  • University of Lorraine
    7
  • Centre Hospitalier Universitaire Amiens-Picardie
    5
  • Centre Hospitalier Universitaire de Besançon
    4
  • Centre Hospitalier Universitaire de Tours
    4
  • Hôpital Cochin
    4
  • Centre Georges François Leclerc
    4
  • Hôpital de la Conception
    4
  • Institut de Cancérologie de Lorraine
    4